The SPC for dabrafenib states that renal failure has been identified in <1 % patients. It advises that patients should be routinely monitored for serum creatinine while on therapy; if creatinine increases, dabrafenib may need to be interrupted as clinically appropriate. The SPC for vemurafenib does not mention the need for routine monitoring of renal function; only the need for close monitoring in those with severe renal impairment.